Newsletter

Pulmonary Arterial Hypertension (PAH)
Emerging therapies in the horizon strive to transform the PAH market landscape
PULMONARY ARTERIAL HYPERTENSION (PAH)

More Whitepapers / Newsletters

Rethinking medtech in Covid times
Rethinking medtech in Covid ti...

COVID-19 transforms healthcare facets at an unprecedented pace. Based on emerging technology, we can be reasonably sure that the bulk of the change will be powered by the digital transformation made p...

Role of Traditional Medicine in COVID-19
Role of Traditional Medicine i...

Doctors and scientists have recognized that traditional, complementary and alternative therapies have many benefits and play an essential role in the treatment of various diseases. Several systematic...

Automated Insulin Delivery Market
Automated Insulin Delivery

Advances in continuous glucose monitoring (CGM) has led to a paradigm shift in the management of type 1 diabetes. The developments have enabled the automation of insulin delivery, where an algorithm d...

Pompe Disease Newsletter
Pompe Disease

An autosomal metabolic disorder – Pompe disease results in deterioration of organs and tissues as a consequence of excess accumulation of glycogen in muscle and nerve cells throughout the body. Also c...

Paroxysmal Nocturnal Hemoglobinuria Newsletter
Paroxysmal Nocturnal Hemoglobi...

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction of red blood cells, blood clots, and an impaired bone marrow caused due to the mutation in the PIGA (...